Table 3. Factors Associated with Acquiring AIDS-Defining Opportunistic Infections during ART.
| Variables | Univariate models, IRR (95%CI), p | Multivariate models, IRR (95%CI), p | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 1,197) | No prior ADIs at baseline (n = 951) | All (n = 1,197) | No prior ADIs at baseline (n = 951) | |||||||||
| Gender male | 2.23 | (1.52–3.25) | <0.001* | 2.80 | (1.83–4.28) | <0.001* | 1.47 | (0.85–2.56) | 0.19 | 1.86 | (0.97–3.57) | 0.06 |
| Age 20–29 | 1 | 1 | 1 | |||||||||
| Age 30–39 | 1.32 | (0.91–1.90) | 0.14 | 0.89 | (0.37–2.17) | 0.804 | 1.34 | (0.82–2.20) | 0.31 | 1.40 | (0.80–2.44) | 0.24 |
| Age 40–49 | 1.29 | (0.75–2.20) | 0.36 | 1.32 | (0.42–4.16) | 0.636 | 1.60 | (0.84–3.04) | 0.15 | 1.59 | (0.75–3.37) | 0.23 |
| Age over 50 | 1.46 | (0.80–2.67) | 0.22 | 0.91 | (0.24–3.52) | 0.892 | 1.83 | (0.81–4.14) | 0.15 | 2.46 | (1.01–5.95) | 0.046* |
| Injection drug use | 1.71 | (1.25–2.34) | 0.001* | 1.93 | (1.36–2.74) | <0.001* | 1.31 | (0.75–2.30) | 0.34 | 1.15 | (0.61–2.16) | 0.68 |
| HBs antigen positive | 1.31 | (0.87–1.98) | 0.19 | 1.43 | (0.92–2.23) | 0.114 | 1.28 | (0.75–2.16) | 0.36 | 1.28 | (0.70–2.35) | 0.43 |
| Anti-HCV antibody positive | 1.83 | (1.31–2.55) | <0.001* | 2.25 | (1.55–3.27) | <0.001* | 1.19 | (0.68–2.10) | 0.55 | 1.54 | (0.81–2.92) | 0.19 |
| CD4<200 at baseline | 9.73 | (3.98–23.9) | <0.001* | 5.70 | (2.32–14.0) | <0.001* | 4.42 | (3.10–19.1) | <0.001* | 6.94 | (2.74–17.0) | <0.001* |
| Prior ADIs at baseline | 0.92 | (0.62–1.36) | 0.68 | - | 0.69 | (0.43–1.10) | 0.12 | - | ||||
IRR: incident rate ratio; CI: confidential interval; ADI: AIDS-defining illness; HBs antigen: hepatitis B surface antigen; HCV: hepatitis C virus
Note:
* Statistically significant (P<0.05)